The goal for the treatment of Parkinson's disease is to stop the loss of dopamine neurons and to induce nerve fibers in those remaining neurons. As a result of the published study, Ceregene is being launched with two key product development programs already under way with the efforts of Neurologic Gene Therapeutics. These include a Phase I clinical trial for Alzheimer's disease gene therapy, as well as successful preclinical studies for Parkinson's disease gene therapy. We will have to wait and see. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.